FibroGen to Report Second Quarter 2025 Financial Results

Group 1 - FibroGen, Inc. will announce its second quarter 2025 financial results on August 11 after market close [1] - A conference call and webcast presentation will be held on the same day at 5:00 PM Eastern Time to discuss financial results and provide a business update [2] - The company is focused on developing novel therapies for cancer biology and anemia, with its drug Roxadustat approved in multiple countries for treating anemia in chronic kidney disease patients [3] Group 2 - FibroGen is also evaluating a development plan for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. [3] - The company is developing FG-3246, a first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer [3] - FG-3180, an associated CD46-targeted PET biomarker, is also in development [4]